STOCK TITAN

[8-K] Aptevo Therapeutics Inc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Barclays Bank PLC is issuing $452,000 of unsecured, unsubordinated Buffered Supertrack SM Notes linked to the price return of the Russell 2000 Index (RTY). The notes are part of the bank’s Global Medium-Term Notes, Series A and will be offered in $1,000 denominations on 30 Jun 2025, maturing 30 Dec 2027.

  • Payout profile – If the index is flat or up at maturity, investors receive principal plus 2× upside, capped at a 31.35 % maximum return ($1,313.50 per $1,000 note).
  • Downside buffer – First 10 % decline is fully protected. Below the 90 % Buffer Value (1,922.57), losses are linear: every additional 1 % drop erodes 1 % of principal, up to a 90 % loss.
  • Key parameters: Initial Value 2,136.185; Upside Leverage 2.0; Buffer 10 %; CUSIP 06746BX71; Estimated value on pricing date $965.70 (≈3.4 % below issue price).
  • Costs & liquidity: 2.75 % selling commission; no exchange listing; Barclays Capital intends, but is not obliged, to make a secondary market.
  • Credit & regulatory risk: Payments depend on Barclays’ creditworthiness and are subject to the U.K. Bail-in Power, meaning principal could be written down or converted to equity during resolution.
  • Tax & withholding: Issuer views the notes as prepaid forward contracts; U.S. tax treatment uncertain; Section 871(m) not expected to apply (delta ≠ 1).

The structure targets investors who can forgo coupons, accept a capped return, and tolerate meaningful equity and issuer risk in exchange for a modest downside buffer and enhanced—though limited—upside participation.

Barclays Bank PLC emette $452.000 di Buffered Supertrack SM Notes non garantite e non subordinate, collegate al rendimento in prezzo dell'indice Russell 2000 (RTY). Le note fanno parte della serie A dei Global Medium-Term Notes della banca e saranno offerte in tagli da $1.000 il 30 giugno 2025, con scadenza il 30 dicembre 2027.

  • Profilo di rendimento – Se l'indice è stabile o in crescita alla scadenza, gli investitori ricevono il capitale più un ritorno doppio rispetto all’aumento, con un rendimento massimo del 31,35% ($1.313,50 per ogni nota da $1.000).
  • Buffer di protezione – Il primo 10% di ribasso è completamente protetto. Sotto il valore di buffer del 90% (1.922,57), le perdite sono lineari: ogni ulteriore calo dell’1% riduce l’1% del capitale, fino a una perdita massima del 90%.
  • Parametri chiave: Valore iniziale 2.136,185; Leva di rialzo 2,0; Buffer 10%; CUSIP 06746BX71; Valore stimato alla data di prezzo $965,70 (circa 3,4% sotto il prezzo di emissione).
  • Costi e liquidità: Commissione di vendita 2,75%; nessuna quotazione in borsa; Barclays Capital intende, ma non è obbligata, a garantire un mercato secondario.
  • Rischio di credito e regolamentare: I pagamenti dipendono dalla solidità creditizia di Barclays e sono soggetti al potere di bail-in del Regno Unito, il che significa che il capitale potrebbe essere ridotto o convertito in azioni in caso di risoluzione.
  • Fiscalità e ritenute: L’emittente considera le note come contratti forward prepagati; trattamento fiscale USA incerto; non si prevede l’applicazione della Sezione 871(m) (delta ≠ 1).

La struttura è rivolta a investitori disposti a rinunciare a cedole, accettare un rendimento massimo e tollerare rischi significativi legati all’equity e all’emittente, in cambio di un buffer di protezione modesto e una partecipazione aumentata – seppur limitata – al rialzo.

Barclays Bank PLC emite $452,000 en Notas Buffered Supertrack SM no garantizadas y no subordinadas, vinculadas al rendimiento del precio del índice Russell 2000 (RTY). Las notas forman parte de la Serie A de los Global Medium-Term Notes del banco y se ofrecerán en denominaciones de $1,000 el 30 de junio de 2025, con vencimiento el 30 de diciembre de 2027.

  • Perfil de pago – Si el índice está estable o sube al vencimiento, los inversores reciben el capital más el doble del alza, con un rendimiento máximo del 31,35% ($1,313.50 por cada nota de $1,000).
  • Buffer a la baja – La primera caída del 10% está completamente protegida. Por debajo del valor de buffer del 90% (1,922.57), las pérdidas son lineales: cada caída adicional del 1% reduce el 1% del capital, hasta una pérdida máxima del 90%.
  • Parámetros clave: Valor inicial 2,136.185; Apalancamiento al alza 2.0; Buffer 10%; CUSIP 06746BX71; Valor estimado en la fecha de precio $965.70 (aprox. 3.4% por debajo del precio de emisión).
  • Costos y liquidez: Comisión de venta del 2.75%; sin cotización en bolsa; Barclays Capital tiene la intención, pero no la obligación, de crear un mercado secundario.
  • Riesgo crediticio y regulatorio: Los pagos dependen de la solvencia de Barclays y están sujetos al poder de rescate (bail-in) del Reino Unido, lo que significa que el capital podría reducirse o convertirse en acciones durante una resolución.
  • Impuestos y retenciones: El emisor considera las notas como contratos forward prepagados; tratamiento fiscal en EE.UU. incierto; no se espera la aplicación de la Sección 871(m) (delta ≠ 1).

La estructura está dirigida a inversores que pueden prescindir de cupones, aceptar un rendimiento limitado y tolerar riesgos significativos de renta variable y del emisor a cambio de un buffer modesto a la baja y una participación mejorada – aunque limitada – al alza.

Barclays Bank PLC는 러셀 2000 지수(RTY)의 가격 수익률에 연계된 $452,000 규모의 무담보 비후순위 Buffered Supertrack SM Notes를 발행합니다. 이 노트는 은행의 글로벌 중기채권 시리즈 A의 일부로, 2025년 6월 30일에 $1,000 단위로 제공되며 만기는 2027년 12월 30일입니다.

  • 지급 프로필 – 만기 시 지수가 변동 없거나 상승하면 투자자는 원금에 2배의 상승 수익을 더해 받으며, 최대 수익률 31.35%($1,000 노트당 $1,313.50)로 상한이 설정됩니다.
  • 하락 보호 버퍼 – 최초 10% 하락은 전액 보호됩니다. 90% 버퍼 값(1,922.57) 이하에서는 손실이 선형적으로 발생하며, 추가 1% 하락 시 원금의 1%가 감소해 최대 90% 손실까지 가능합니다.
  • 주요 파라미터: 초기 값 2,136.185; 상승 레버리지 2.0; 버퍼 10%; CUSIP 06746BX71; 가격 결정일 추정 가치 $965.70 (발행가 대비 약 3.4% 낮음).
  • 비용 및 유동성: 판매 수수료 2.75%; 거래소 상장 없음; Barclays Capital은 2차 시장 조성을 의도하지만 의무는 아닙니다.
  • 신용 및 규제 위험: 지급은 Barclays의 신용도에 의존하며, 영국의 베일인 권한에 따라 원금이 감액되거나 주식으로 전환될 수 있습니다.
  • 세금 및 원천징수: 발행자는 노트를 선불 선도계약으로 간주하며, 미국 세금 처리는 불확실하고, 섹션 871(m)은 적용되지 않을 것으로 예상됩니다 (델타 ≠ 1).

이 구조는 쿠폰을 포기할 수 있고, 수익 상한을 수용하며, 적당한 하락 보호와 제한적이나마 향상된 상승 참여를 대가로 상당한 주식 및 발행자 위험을 감수할 수 있는 투자자를 대상으로 합니다.

Barclays Bank PLC émet 452 000 $ de Buffered Supertrack SM Notes non garanties et non subordonnées, liées à la performance en prix de l'indice Russell 2000 (RTY). Les notes font partie de la série A des Global Medium-Term Notes de la banque et seront proposées en coupures de 1 000 $ le 30 juin 2025, avec une échéance au 30 décembre 2027.

  • Profil de paiement – Si l'indice est stable ou en hausse à l'échéance, les investisseurs reçoivent le principal plus 2× la hausse, plafonné à un rendement maximum de 31,35 % (1 313,50 $ par note de 1 000 $).
  • Protection à la baisse – La première baisse de 10 % est entièrement protégée. En dessous de la valeur tampon à 90 % (1 922,57), les pertes sont linéaires : chaque baisse supplémentaire de 1 % réduit 1 % du principal, jusqu'à une perte maximale de 90 %.
  • Paramètres clés : Valeur initiale 2 136,185 ; Effet de levier haussier 2,0 ; Tampon 10 % ; CUSIP 06746BX71 ; Valeur estimée à la date de tarification 965,70 $ (environ 3,4 % en dessous du prix d'émission).
  • Coûts et liquidité : Commission de vente de 2,75 % ; pas de cotation en bourse ; Barclays Capital a l'intention, mais n'est pas obligé, de créer un marché secondaire.
  • Risque de crédit et réglementaire : Les paiements dépendent de la solvabilité de Barclays et sont soumis au pouvoir de bail-in du Royaume-Uni, ce qui signifie que le principal pourrait être réduit ou converti en actions en cas de résolution.
  • Fiscalité et retenues : L’émetteur considère les notes comme des contrats à terme prépayés ; traitement fiscal américain incertain ; la Section 871(m) ne devrait pas s’appliquer (delta ≠ 1).

Cette structure s’adresse aux investisseurs pouvant renoncer aux coupons, accepter un rendement plafonné et tolérer des risques importants liés aux actions et à l’émetteur, en échange d’un tampon modeste à la baisse et d’une participation améliorée – bien que limitée – à la hausse.

Barclays Bank PLC gibt unverbriefte, unbesicherte Buffered Supertrack SM Notes im Wert von 452.000 $ aus, die an die Kursrendite des Russell 2000 Index (RTY) gekoppelt sind. Die Notes gehören zur Serie A der Global Medium-Term Notes der Bank und werden am 30. Juni 2025 in Stückelungen zu je 1.000 $ angeboten, mit Fälligkeit am 30. Dezember 2027.

  • Auszahlungsprofil – Liegt der Index bei Fälligkeit unverändert oder höher, erhalten Anleger das Kapital plus das 2-fache der Kurssteigerung, begrenzt auf eine maximale Rendite von 31,35 % (1.313,50 $ pro 1.000 $ Note).
  • Downside-Buffer – Die ersten 10 % Kursrückgang sind vollständig geschützt. Unterhalb des 90 %-Buffer-Werts (1.922,57) sind Verluste linear: Jeder weitere 1 % Rückgang mindert 1 % des Kapitals, bis zu einem maximalen Verlust von 90 %.
  • Wichtige Parameter: Anfangswert 2.136,185; Upside-Leverage 2,0; Buffer 10 %; CUSIP 06746BX71; Geschätzter Wert am Pricing-Tag 965,70 $ (ca. 3,4 % unter dem Ausgabepreis).
  • Kosten & Liquidität: 2,75 % Verkaufsprovision; keine Börsennotierung; Barclays Capital beabsichtigt, aber ist nicht verpflichtet, einen Sekundärmarkt zu schaffen.
  • Kredit- & Regulatorisches Risiko: Zahlungen hängen von der Kreditwürdigkeit von Barclays ab und unterliegen der britischen Bail-in-Regelung, was bedeutet, dass das Kapital im Falle einer Abwicklung abgeschrieben oder in Eigenkapital umgewandelt werden kann.
  • Steuer & Quellensteuer: Emittent betrachtet die Notes als vorausbezahlte Terminkontrakte; US-Steuerbehandlung unklar; Anwendung von Section 871(m) wird nicht erwartet (Delta ≠ 1).

Die Struktur richtet sich an Anleger, die auf Kupons verzichten können, eine begrenzte Rendite akzeptieren und bedeutende Aktien- und Emittentenrisiken tolerieren, im Tausch gegen einen moderaten Downside-Buffer und eine verbesserte – wenn auch begrenzte – Aufwärtsbeteiligung.

Positive
  • 10 % downside buffer absorbs moderate equity declines before principal is at risk.
  • 2× upside participation up to a 31.35 % cap enables enhanced returns versus direct RTY exposure within a defined range.
  • Short 2.5-year tenor reduces duration exposure relative to longer-dated structured notes.
Negative
  • Maximum return is capped at 31.35 %, limiting gains if the Russell 2000 rallies strongly.
  • Up to 90 % principal loss once the index falls more than 10 %, exposing investors to significant downside.
  • Estimated value ($965.70) is materially below issue price, indicating ~3.4 % embedded costs at launch.
  • Issuer credit and U.K. bail-in risk mean repayment depends on Barclays’ solvency and regulatory actions.
  • No exchange listing and small deal size could result in poor secondary-market liquidity.

Insights

TL;DR – Leverage to 31 % upside with 10 % buffer, but high issuer and liquidity risk makes outcome highly path-dependent.

The notes offer a clear risk-reward trade-off: double the small-cap upside until 15.675 % index appreciation, after which returns are capped. The 10 % buffer is typical for two-to-three-year retail structures and will only absorb mild equity drawdowns; beyond that, losses accelerate 1-for-1. Investors effectively exchange dividend rights and uncapped growth for leveraged but limited participation plus serious tail risk. Pricing is expensive: the bank’s own model value ($965.70) sits 34.3 points below issue price, largely covering the 2.75 % commission, hedging costs and issuer margin. Credit exposure to Barclays and potential bail-in further differentiate this from traditional debt.

Because secondary liquidity is dealer-driven, exit pricing will incorporate both bid/ask spreads and issuer credit spreads, typically leaving early sellers at a material discount. The small $452k deal size suggests limited aftermarket depth. Overall, the note may suit fee-based accounts seeking defined-outcome exposure to U.S. small caps over 30 months, provided they are comfortable with credit, liquidity, and buffer limitations.

TL;DR – Niche, short-dated defined-outcome note best viewed as tactical satellite, not core holding.

Strategically, the instrument behaves like a short-put/long-call spread on the Russell 2000 layered over a Barclays credit note. At issuance, the embedded option premium (difference between $1,000 price and $965.70 model value) approximates 3.5 %, implying investors overpay relative to delta-hedged replication. The 31.35 % cap translates to an annualized 11.8 % max yield—attractive if the investor’s bullish view materializes inside two years, but structurally inferior to simply holding RTY ETF beyond the cap. In stressed equity markets, the 90 % potential loss combined with Barclays’ bail-in risk could materially impair portfolios. Thus, allocation should be limited and paired with diversified credit exposure.

Barclays Bank PLC emette $452.000 di Buffered Supertrack SM Notes non garantite e non subordinate, collegate al rendimento in prezzo dell'indice Russell 2000 (RTY). Le note fanno parte della serie A dei Global Medium-Term Notes della banca e saranno offerte in tagli da $1.000 il 30 giugno 2025, con scadenza il 30 dicembre 2027.

  • Profilo di rendimento – Se l'indice è stabile o in crescita alla scadenza, gli investitori ricevono il capitale più un ritorno doppio rispetto all’aumento, con un rendimento massimo del 31,35% ($1.313,50 per ogni nota da $1.000).
  • Buffer di protezione – Il primo 10% di ribasso è completamente protetto. Sotto il valore di buffer del 90% (1.922,57), le perdite sono lineari: ogni ulteriore calo dell’1% riduce l’1% del capitale, fino a una perdita massima del 90%.
  • Parametri chiave: Valore iniziale 2.136,185; Leva di rialzo 2,0; Buffer 10%; CUSIP 06746BX71; Valore stimato alla data di prezzo $965,70 (circa 3,4% sotto il prezzo di emissione).
  • Costi e liquidità: Commissione di vendita 2,75%; nessuna quotazione in borsa; Barclays Capital intende, ma non è obbligata, a garantire un mercato secondario.
  • Rischio di credito e regolamentare: I pagamenti dipendono dalla solidità creditizia di Barclays e sono soggetti al potere di bail-in del Regno Unito, il che significa che il capitale potrebbe essere ridotto o convertito in azioni in caso di risoluzione.
  • Fiscalità e ritenute: L’emittente considera le note come contratti forward prepagati; trattamento fiscale USA incerto; non si prevede l’applicazione della Sezione 871(m) (delta ≠ 1).

La struttura è rivolta a investitori disposti a rinunciare a cedole, accettare un rendimento massimo e tollerare rischi significativi legati all’equity e all’emittente, in cambio di un buffer di protezione modesto e una partecipazione aumentata – seppur limitata – al rialzo.

Barclays Bank PLC emite $452,000 en Notas Buffered Supertrack SM no garantizadas y no subordinadas, vinculadas al rendimiento del precio del índice Russell 2000 (RTY). Las notas forman parte de la Serie A de los Global Medium-Term Notes del banco y se ofrecerán en denominaciones de $1,000 el 30 de junio de 2025, con vencimiento el 30 de diciembre de 2027.

  • Perfil de pago – Si el índice está estable o sube al vencimiento, los inversores reciben el capital más el doble del alza, con un rendimiento máximo del 31,35% ($1,313.50 por cada nota de $1,000).
  • Buffer a la baja – La primera caída del 10% está completamente protegida. Por debajo del valor de buffer del 90% (1,922.57), las pérdidas son lineales: cada caída adicional del 1% reduce el 1% del capital, hasta una pérdida máxima del 90%.
  • Parámetros clave: Valor inicial 2,136.185; Apalancamiento al alza 2.0; Buffer 10%; CUSIP 06746BX71; Valor estimado en la fecha de precio $965.70 (aprox. 3.4% por debajo del precio de emisión).
  • Costos y liquidez: Comisión de venta del 2.75%; sin cotización en bolsa; Barclays Capital tiene la intención, pero no la obligación, de crear un mercado secundario.
  • Riesgo crediticio y regulatorio: Los pagos dependen de la solvencia de Barclays y están sujetos al poder de rescate (bail-in) del Reino Unido, lo que significa que el capital podría reducirse o convertirse en acciones durante una resolución.
  • Impuestos y retenciones: El emisor considera las notas como contratos forward prepagados; tratamiento fiscal en EE.UU. incierto; no se espera la aplicación de la Sección 871(m) (delta ≠ 1).

La estructura está dirigida a inversores que pueden prescindir de cupones, aceptar un rendimiento limitado y tolerar riesgos significativos de renta variable y del emisor a cambio de un buffer modesto a la baja y una participación mejorada – aunque limitada – al alza.

Barclays Bank PLC는 러셀 2000 지수(RTY)의 가격 수익률에 연계된 $452,000 규모의 무담보 비후순위 Buffered Supertrack SM Notes를 발행합니다. 이 노트는 은행의 글로벌 중기채권 시리즈 A의 일부로, 2025년 6월 30일에 $1,000 단위로 제공되며 만기는 2027년 12월 30일입니다.

  • 지급 프로필 – 만기 시 지수가 변동 없거나 상승하면 투자자는 원금에 2배의 상승 수익을 더해 받으며, 최대 수익률 31.35%($1,000 노트당 $1,313.50)로 상한이 설정됩니다.
  • 하락 보호 버퍼 – 최초 10% 하락은 전액 보호됩니다. 90% 버퍼 값(1,922.57) 이하에서는 손실이 선형적으로 발생하며, 추가 1% 하락 시 원금의 1%가 감소해 최대 90% 손실까지 가능합니다.
  • 주요 파라미터: 초기 값 2,136.185; 상승 레버리지 2.0; 버퍼 10%; CUSIP 06746BX71; 가격 결정일 추정 가치 $965.70 (발행가 대비 약 3.4% 낮음).
  • 비용 및 유동성: 판매 수수료 2.75%; 거래소 상장 없음; Barclays Capital은 2차 시장 조성을 의도하지만 의무는 아닙니다.
  • 신용 및 규제 위험: 지급은 Barclays의 신용도에 의존하며, 영국의 베일인 권한에 따라 원금이 감액되거나 주식으로 전환될 수 있습니다.
  • 세금 및 원천징수: 발행자는 노트를 선불 선도계약으로 간주하며, 미국 세금 처리는 불확실하고, 섹션 871(m)은 적용되지 않을 것으로 예상됩니다 (델타 ≠ 1).

이 구조는 쿠폰을 포기할 수 있고, 수익 상한을 수용하며, 적당한 하락 보호와 제한적이나마 향상된 상승 참여를 대가로 상당한 주식 및 발행자 위험을 감수할 수 있는 투자자를 대상으로 합니다.

Barclays Bank PLC émet 452 000 $ de Buffered Supertrack SM Notes non garanties et non subordonnées, liées à la performance en prix de l'indice Russell 2000 (RTY). Les notes font partie de la série A des Global Medium-Term Notes de la banque et seront proposées en coupures de 1 000 $ le 30 juin 2025, avec une échéance au 30 décembre 2027.

  • Profil de paiement – Si l'indice est stable ou en hausse à l'échéance, les investisseurs reçoivent le principal plus 2× la hausse, plafonné à un rendement maximum de 31,35 % (1 313,50 $ par note de 1 000 $).
  • Protection à la baisse – La première baisse de 10 % est entièrement protégée. En dessous de la valeur tampon à 90 % (1 922,57), les pertes sont linéaires : chaque baisse supplémentaire de 1 % réduit 1 % du principal, jusqu'à une perte maximale de 90 %.
  • Paramètres clés : Valeur initiale 2 136,185 ; Effet de levier haussier 2,0 ; Tampon 10 % ; CUSIP 06746BX71 ; Valeur estimée à la date de tarification 965,70 $ (environ 3,4 % en dessous du prix d'émission).
  • Coûts et liquidité : Commission de vente de 2,75 % ; pas de cotation en bourse ; Barclays Capital a l'intention, mais n'est pas obligé, de créer un marché secondaire.
  • Risque de crédit et réglementaire : Les paiements dépendent de la solvabilité de Barclays et sont soumis au pouvoir de bail-in du Royaume-Uni, ce qui signifie que le principal pourrait être réduit ou converti en actions en cas de résolution.
  • Fiscalité et retenues : L’émetteur considère les notes comme des contrats à terme prépayés ; traitement fiscal américain incertain ; la Section 871(m) ne devrait pas s’appliquer (delta ≠ 1).

Cette structure s’adresse aux investisseurs pouvant renoncer aux coupons, accepter un rendement plafonné et tolérer des risques importants liés aux actions et à l’émetteur, en échange d’un tampon modeste à la baisse et d’une participation améliorée – bien que limitée – à la hausse.

Barclays Bank PLC gibt unverbriefte, unbesicherte Buffered Supertrack SM Notes im Wert von 452.000 $ aus, die an die Kursrendite des Russell 2000 Index (RTY) gekoppelt sind. Die Notes gehören zur Serie A der Global Medium-Term Notes der Bank und werden am 30. Juni 2025 in Stückelungen zu je 1.000 $ angeboten, mit Fälligkeit am 30. Dezember 2027.

  • Auszahlungsprofil – Liegt der Index bei Fälligkeit unverändert oder höher, erhalten Anleger das Kapital plus das 2-fache der Kurssteigerung, begrenzt auf eine maximale Rendite von 31,35 % (1.313,50 $ pro 1.000 $ Note).
  • Downside-Buffer – Die ersten 10 % Kursrückgang sind vollständig geschützt. Unterhalb des 90 %-Buffer-Werts (1.922,57) sind Verluste linear: Jeder weitere 1 % Rückgang mindert 1 % des Kapitals, bis zu einem maximalen Verlust von 90 %.
  • Wichtige Parameter: Anfangswert 2.136,185; Upside-Leverage 2,0; Buffer 10 %; CUSIP 06746BX71; Geschätzter Wert am Pricing-Tag 965,70 $ (ca. 3,4 % unter dem Ausgabepreis).
  • Kosten & Liquidität: 2,75 % Verkaufsprovision; keine Börsennotierung; Barclays Capital beabsichtigt, aber ist nicht verpflichtet, einen Sekundärmarkt zu schaffen.
  • Kredit- & Regulatorisches Risiko: Zahlungen hängen von der Kreditwürdigkeit von Barclays ab und unterliegen der britischen Bail-in-Regelung, was bedeutet, dass das Kapital im Falle einer Abwicklung abgeschrieben oder in Eigenkapital umgewandelt werden kann.
  • Steuer & Quellensteuer: Emittent betrachtet die Notes als vorausbezahlte Terminkontrakte; US-Steuerbehandlung unklar; Anwendung von Section 871(m) wird nicht erwartet (Delta ≠ 1).

Die Struktur richtet sich an Anleger, die auf Kupons verzichten können, eine begrenzte Rendite akzeptieren und bedeutende Aktien- und Emittentenrisiken tolerieren, im Tausch gegen einen moderaten Downside-Buffer und eine verbesserte – wenn auch begrenzte – Aufwärtsbeteiligung.

0001671584false00016715842025-06-302025-06-30

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 30, 2025

 

 

APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37746

81-1567056

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2401 4th Avenue

Suite 1050

 

Seattle, Washington

 

98121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (206) 838-0500

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

APVO

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 8.01 Other Events.

As previously disclosed, Aptevo Therapeutics Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the quarter ended March 31, 2025, the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on Nasdaq. During the quarterly period ended June 30, 2025, the Company raised gross proceeds of approximately $15.9 million of additional equity capital and, as a result, believes it has stockholders’ equity of at least $2.5 million and is in compliance with the Rule.

Specifically, (i) on April 4, 2025, the Company completed a registered direct offering of the Company’s common stock and a concurrent private placement of warrants and received gross proceeds of approximately $2.1 million; (ii) on April 22, 2025, the Company completed a registered direct offering of the Company’s common stock and received gross proceeds of approximately $2.0 million; (iii) on June 20, 2025, the Company completed a registered direct offering of the Company’s common stock (or pre-funded warrants in lieu thereof) and warrants and received gross proceeds of approximately $8.0 million; and (iv) pursuant to that certain At The Market Offering Agreement entered into with Roth Capital Partners on April 28, 2025, the Company sold shares of the Company’s common stock for aggregate gross proceeds of approximately $3.8 million.

As a result of these equity offerings, the Company believes, as of the date of this filing, it has stockholders’ equity of at least $2.5 million. The Company awaits formal confirmation from Nasdaq that it has evidenced compliance with the Rule, and will provide an update to the market upon receipt of a compliance determination from Nasdaq.

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

APTEVO THERAPEUTICS INC.

 

 

 

 

Date:

June 30, 2025

By:

/s/ Marvin L. White

 

 

 

Marvin L. White
President and Chief Executive Officer

 


FAQ

What is the upside cap for Barclays VXZ Buffered Supertrack Notes?

The notes cap total return at 31.35 %, delivering a maximum payment of $1,313.50 per $1,000 note.

How much protection does the 10 % buffer provide on the Russell 2000 Index?

If the index ends within 10 % below its initial level, investors receive full principal; below that, losses are 1-for-1.

What are the key dates for these 424B2 notes?

Initial Valuation 25 Jun 2025; Issue 30 Jun 2025; Final Valuation 27 Dec 2027; Maturity 30 Dec 2027.

How do selling commissions impact investor proceeds?

Barclays Capital earns a 2.75 % commission, contributing to the gap between the $1,000 price and $965.70 estimated value.

Are the notes listed or easily tradable before maturity?

No. The notes will not be listed; any secondary trading depends solely on dealer willingness, with potentially wide spreads.

How does the U.K. Bail-in Power affect investors?

Regulators can write down or convert the notes if Barclays is in resolution, which could wipe out principal irrespective of index performance.
Aptevo Therapeutics Inc

NASDAQ:APVO

APVO Rankings

APVO Latest News

APVO Latest SEC Filings

APVO Stock Data

10.48M
738.10k
0.01%
4.85%
4.12%
Biotechnology
Pharmaceutical Preparations
Link
United States
SEATTLE